Source: ReNeuron Group plc
Date: 16 November 2010
Summary:
Guildford, UK - ReNeuron Group plc today announces that the first patient has been treated with the Company’s ReN001 stem cell therapy for stroke in a ground-breaking UK clinical trial. The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world’s first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients. ReNeuron is the first company to have received regulatory approval for any stem cell-based clinical trial in the UK. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.
